AVR RD 03
Alternative Names: AVR-RD-03Latest Information Update: 25 Jun 2024
At a glance
- Originator AVROBIO
- Developer Tectonic Therapeutic
- Class Cell therapies; Gene therapies; Haematopoietic stem cells therapies; Stem cell therapies
- Mechanism of Action Alpha-glucosidase stimulants; Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Suspended Glycogen storage disease type II
Most Recent Events
- 20 Jun 2024 AVROBIO has been merged with Tectonic Therapeutic to form Tectonic Therapeutic
- 12 Jul 2023 Suspended - Preclinical for Glycogen storage disease type II in USA (Parenteral) as AVROBIO is exploring strategic alternatives
- 31 Dec 2022 AVROBIO has a patent pending for AVR RD 03 pertaining to claims directed to CD34+ stem cells expressing acid alpha-glucosidase and methods of using the same for the treatment of Glycogen storage disease type II in USA